<DOC>
	<DOCNO>NCT01352663</DOCNO>
	<brief_summary>This open label , randomize , parallel group comparison immunogenicity safety Wockhardt 's Recombinant Insulin Analogue innovator 's Glargine Type 1 diabetic patient .</brief_summary>
	<brief_title>Immunogenicity Safety Study Wockhardt 's Recombinant Insulin Analogue Type 1 Diabetic Patients</brief_title>
	<detailed_description>To evaluate compare Immunogenicity Safety Wockhardt 's Recombinant Insulin Analogue innovator 's Glargine .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>1 . Patients prediagnosed case type1 diabetes period less 1 year 2 . Male Female Patients &gt; = 18 = &lt; 55 year age . 3 . Patients BMI 18.0 30.0 kg/m2 4 . Patients cooperative , reliable , agree regular injection insulin willing comply protocol procedure . 1 . A Patient pregnant currently breastfeed . 2 . A Patient history severe hypoglycemia within past year 3 . A Patient employee Investigator , patient direct involvement trial trial direction Investigator . 4 . Patients Hepatitis B C positive test positive medical history HIV screening . 5 . Patients unlikely comply study protocol e.g . unable return periodically subsequent visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Type I Diabetes</keyword>
	<keyword>Wockhardt</keyword>
	<keyword>Insulin Analogue</keyword>
</DOC>